India, July 10 -- Danish pharmaceutical giant Novo Nordisk, on June 9, launched Awiqli, its once-weekly basal insulin injection, in India, positioning it as a major advancement in diabetes care that could significantly reduce the number of insulin injections required by patients.

The new therapy is expected to reduce the annual number of basal insulin injections for eligible patients from 365 to just 52, offering a more convenient treatment option for adults with Type 2 diabetes.

"When we are launching Awiqli, you called it a disruption. I call it a solution for Type 2 diabetes," Shrotriya said.

According to NDTV, the 1 ml Awiqli FlexTouch pen, containing 700 units of insulin, is priced at Rs 2,611, while the 3 ml pen, containing 2,100...